<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01764529</url>
  </required_header>
  <id_info>
    <org_study_id>BVMC 6201</org_study_id>
    <secondary_id>U54NS065705</secondary_id>
    <nct_id>NCT01764529</nct_id>
  </id_info>
  <brief_title>Modifiers of Disease Severity in Cerebral Cavernous Malformations</brief_title>
  <official_title>Modifiers of Disease Severity and Progression in Cerebral Cavernous Malformations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Childrenâ€™s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barrow Neurological Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Angioma Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain
      and spine. CCMs can bleed and cause strokes, seizures, and headaches. CCMs are often caused
      by an inherited gene mutation (alteration) in one of three CCM genes (CCM1, CCM2, or CCM3).
      There is a wide range of disease severity even among family members with this disease, though
      the natural history has not been clearly described for this particular population.

      This study will continue to enroll and follow participants with familial CCM to identify
      factors that influence CCM disease severity and progression, focusing on barriers to clinical
      trial preparedness. Our long-term goal is to identify measurable outcomes and robust
      biomarkers that will help select high-risk patients and help monitor drug response in future
      clinical trials. The specific goals of this study are to:

      identify factors that influence lesion progression to symptomatic hemorrhage and other
      outcomes, including quality of life; investigate the role of the gut microbiome and lesion
      burden in CCM disease, and establish blood biomarkers predictive of CCM disease severity and
      progression for clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is one of three projects participating in the Brain Vascular Malformation
      Consortium (BVMC) funded by the Office of Rare Diseases Research, which is part of the
      National Center for Advancing Translational Sciences (NCATS), and the National Institute of
      Neurological Disorders and Stroke (NINDS).

      The CCM project is a cross-sectional and longitudinal study of familial CCM patients. The
      study is currently in the third 5-year cycle. During the first 5 year cycle (BVMC1), the CCM
      project was focused on recruiting CCM1 cases with the common Hispanic mutation (CHM). In the
      second 5-year cycle (BVMC2), we expanded recruitment to include not only CCM1-CHM cases, but
      also other CCM familial patients and mutation carriers. In the third 5-year cycle (BVMC3), we
      will continue to recruit familial CCM cases and expand to additional recruitment sites.

      We collect clinical, genetic, imaging, treatment, and outcome data in participants, and
      follow enrolled participants over time to understand the natural history of this disease.

      For new study participants, you will be asked to:

      Give permission for study staff to access your medical records to collect clinical
      information and to obtain copies of MRI scans and reports.

      Fill out a questionnaire about your quality of life, family history, and medical/surgical
      history.

      Give a blood and/or saliva sample, and stool sample.

      Give permission to store and use your CCM resected tissue for research (if undergoing
      surgery).

      Participate in annual follow-ups to update medical, surgical, and neurological information.

      Eligible cases include those with a known genetic mutation in one of the three CCM genes or
      those that meet 2 of 3 following clinical criteria:

        1. Clinical diagnosis of CCM,

        2. Multi-focal lesions on MRI, and/or

        3. Family history of CCMs.

      Exclusion Criteria:

        1. Patients who cannot or are unwilling to sign informed consent and for whom no
           appropriate surrogate is available.

        2. Prisoners and homeless individuals because of the inability to contact the subject and
           collect follow-up data using standard procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Total CCM lesion number per patient</measure>
    <time_frame>Baseline</time_frame>
    <description>The number of lesions (or cavernous angiomas) located in the brain will be counted by a neuroradiologist and by an automated algorithm developed as part of this project.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of symptomatic hemorrhage</measure>
    <time_frame>Baseline and annual assessment</time_frame>
    <description>Symptomatic hemorrhage is defined as diagnostic evidence of new lesional bleeding or hemorrhagic growth, in association with directly attributable symptoms. Rate of symptomatic hemorrhage and the factors that influence hemorhrage rates will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lesion number</measure>
    <time_frame>Baseline, Follow up MRI</time_frame>
    <description>The number of lesions (or cavernous angiomas) counted on the baseline MRI will be compared to the number of lesions observed in follow up MRIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin score</measure>
    <time_frame>Baseline and annual assessment</time_frame>
    <description>The modified Rankin score will be assessed at baseline and at approximately one year intervals while remaining in study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-Reported Quality of Life (QoL) (The NIH PROMIS-29)</measure>
    <time_frame>Baseline and annual assessment</time_frame>
    <description>Standardized patient reported outcome measurement tools to assess pain, fatigue, physical function, emotional distress, and social participation.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Cavernous Angioma, Familial</condition>
  <condition>Cerebral Cavernous Malformations</condition>
  <condition>Cerebral Cavernous Hemangioma</condition>
  <arm_group>
    <arm_group_label>The BVMC FCCM cohort</arm_group_label>
    <description>Aim 1: To investigate the relationship between lesion burden and outcomes in FCCM.
Aim 2: To investigate the role of the gut microbiome in FCCM disease severity. Aim 3: To establish blood markers predictive of disease severity and progression for medical treatment of CCM.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will collect stool specimens in newly recruited FCCM cases. We store saliva as well as
      whole blood for DNA, RNA, and plasma or serum samples. Brain cavernous malformation tissue
      will be collected and banked as available.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes individuals who carry the diagnosis of familial cerebral
        cavernous malformation (CCM), both symptomatic and asymptomatic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individual has a CCM mutation confirmed through DNA testing, or

          -  Individual meets 2 or more of the following clinical criteria:

               1. Clinical diagnosis of CCM

               2. Multi-focal CCMs on MRI

               3. Family history of CCM

        Exclusion Criteria:

          1. Individuals who are incarcerated

          2. Individuals who are homeless

          3. Unable or unwilling to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atif Zafar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Issam Awad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Kim, PhD</last_name>
    <phone>415-206-8906</phone>
    <email>helen.kim2@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andres Alvarez Pinzon, PhD, MD</last_name>
    <phone>415-476-2677</phone>
    <email>andres.alvarezpinzon@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norissa Honea</last_name>
      <phone>602-406-6267</phone>
      <email>Norissa.Honea@DignityHealth.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Zabramski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael T. Lawton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avery Lui</last_name>
      <phone>415-476-2680</phone>
      <email>avery.lui@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Helen Kim, PhD</last_name>
      <phone>415-206-8906</phone>
      <email>helen.kim2@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Helen Kim, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago, Medicine and Biological Sciences</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Issam Awad, MD</last_name>
      <phone>773-702-8996</phone>
      <email>iawad@surgery.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Agnieszka Stadnik, MS, CCRP</last_name>
      <phone>(773) 702-8996</phone>
      <email>astadnik@surgery.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Issam Awad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tina Mounlavongsy, MPH, CDA</last_name>
      <phone>617-355-8310</phone>
      <email>tina.mounlavongsy@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Edward R. Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atif Zafar, MD</last_name>
      <phone>505-272-3194</phone>
      <email>azafar@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Richard Torres</last_name>
      <phone>505 272-3194</phone>
      <email>riatorres@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Atif Zafar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Mabray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Angioma Alliance</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital, Division of Pediatric Neurosurgery, Cerebrovascular Program</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ashton Roach, MS</last_name>
      <phone>513-803-7621</phone>
      <email>Ashton.Roach@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Sudhakar Vadivelu, DO</last_name>
      <phone>513-803-7621</phone>
      <email>Sudhakar.Vadivelu@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sudhakar Vadivelu, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.angiomaalliance.org/</url>
    <description>Angioma Alliance is an organization by and for those affected by cavernous angiomas and their loved ones, health professionals, and researchers.</description>
  </link>
  <reference>
    <citation>Choquet H, Pawlikowska L, Nelson J, McCulloch CE, Akers A, Baca B, Khan Y, Hart B, Morrison L, Kim H; Brain Vascular Malformation Consortium (BVMC) Study. Polymorphisms in inflammatory and immune response genes associated with cerebral cavernous malformation type 1 severity. Cerebrovasc Dis. 2014;38(6):433-40. doi: 10.1159/000369200. Epub 2014 Dec 3.</citation>
    <PMID>25472749</PMID>
  </reference>
  <reference>
    <citation>Choquet H, Nelson J, Pawlikowska L, McCulloch CE, Akers A, Baca B, Khan Y, Hart B, Morrison L, Kim H. Association of cardiovascular risk factors with disease severity in cerebral cavernous malformation type 1 subjects with the common Hispanic mutation. Cerebrovasc Dis. 2014;37(1):57-63. doi: 10.1159/000356839. Epub 2013 Dec 21.</citation>
    <PMID>24401931</PMID>
  </reference>
  <reference>
    <citation>Golden M, Saeidi S, Liem B, Marchand E, Morrison L, Hart B. Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation. J Med Imaging Radiat Oncol. 2015 Feb;59(1):134-6. doi: 10.1111/1754-9485.12269. Epub 2015 Jan 7.</citation>
    <PMID>25565562</PMID>
  </reference>
  <reference>
    <citation>Hart BL, Taheri S, Rosenberg GA, Morrison LA. Dynamic contrast-enhanced MRI evaluation of cerebral cavernous malformations. Transl Stroke Res. 2013 Oct;4(5):500-6. doi: 10.1007/s12975-013-0285-y. Epub 2013 Sep 21.</citation>
    <PMID>24323376</PMID>
  </reference>
  <reference>
    <citation>Akers AL, Ball KL, Clancy M, Comi AM, Faughnan ME, Gopal-Srivastava R, Jacobs TP, Kim H, Krischer J, Marchuk DA, McCulloch CE, Morrison L, Moses M, Moy CS, Pawlikowska L, Young WL. Brain Vascular Malformation Consortium: Overview, Progress and Future Directions. J Rare Disord. 2013 Apr 1;1(1):5.</citation>
    <PMID>25221778</PMID>
  </reference>
  <reference>
    <citation>Petersen TA, Morrison LA, Schrader RM, Hart BL. Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype. AJNR Am J Neuroradiol. 2010 Feb;31(2):377-82. doi: 10.3174/ajnr.A1822. Epub 2009 Oct 15.</citation>
    <PMID>19833796</PMID>
  </reference>
  <reference>
    <citation>Choquet H, Trapani E, Goitre L, Trabalzini L, Akers A, Fontanella M, Hart BL, Morrison LA, Pawlikowska L, Kim H, Retta SF. Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1. Free Radic Biol Med. 2016 Mar;92:100-109. doi: 10.1016/j.freeradbiomed.2016.01.008. Epub 2016 Jan 19.</citation>
    <PMID>26795600</PMID>
  </reference>
  <reference>
    <citation>Golden MJ, Morrison LA, Kim H, Hart BL. Increased number of white matter lesions in patients with familial cerebral cavernous malformations. AJNR Am J Neuroradiol. 2015 May;36(5):899-903. doi: 10.3174/ajnr.A4200. Epub 2015 Jan 2.</citation>
    <PMID>25556204</PMID>
  </reference>
  <reference>
    <citation>Zou X, Hart BL, Mabray M, Bartlett MR, Bian W, Nelson J, Morrison LA, McCulloch CE, Hess CP, Lupo JM, Kim H. Automated algorithm for counting microbleeds in patients with familial cerebral cavernous malformations. Neuroradiology. 2017 Jul;59(7):685-690. doi: 10.1007/s00234-017-1845-8. Epub 2017 May 22.</citation>
    <PMID>28534135</PMID>
  </reference>
  <reference>
    <citation>Strickland CD, Eberhardt SC, Bartlett MR, Nelson J, Kim H, Morrison LA, Hart BL. Familial Cerebral Cavernous Malformations Are Associated with Adrenal Calcifications on CT Scans: An Imaging Biomarker for a Hereditary Cerebrovascular Condition. Radiology. 2017 Aug;284(2):443-450. doi: 10.1148/radiol.2017161127. Epub 2017 Mar 20.</citation>
    <PMID>28318403</PMID>
  </reference>
  <reference>
    <citation>Akers A, Al-Shahi Salman R, A Awad I, Dahlem K, Flemming K, Hart B, Kim H, Jusue-Torres I, Kondziolka D, Lee C, Morrison L, Rigamonti D, Rebeiz T, Tournier-Lasserve E, Waggoner D, Whitehead K. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery. 2017 May 1;80(5):665-680. doi: 10.1093/neuros/nyx091. Review.</citation>
    <PMID>28387823</PMID>
  </reference>
  <reference>
    <citation>Morrison L, Akers A. Cerebral Cavernous Malformation, Familial. 2003 Feb 24 [updated 2016 Aug 4]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviewsÂ® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from http://www.ncbi.nlm.nih.gov/books/NBK1293/</citation>
    <PMID>20301470</PMID>
  </reference>
  <reference>
    <citation>Choquet H, Pawlikowska L, Lawton MT, Kim H. Genetics of cerebral cavernous malformations: current status and future prospects. J Neurosurg Sci. 2015 Sep;59(3):211-20. Epub 2015 Apr 22. Review.</citation>
    <PMID>25900426</PMID>
  </reference>
  <reference>
    <citation>Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N, Girard R, Zeineddine HA, Lightle R, Moore T, Cao Y, Shenkar R, Chen M, Mericko P, Yang J, Li L, Tanes C, Kobuley D, VÃµsa U, Whitehead KJ, Li DY, Franke L, Hart B, Schwaninger M, Henao-Mejia J, Morrison L, Kim H, Awad IA, Zheng X, Kahn ML. Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017 May 18;545(7654):305-310. doi: 10.1038/nature22075. Epub 2017 May 10.</citation>
    <PMID>28489816</PMID>
  </reference>
  <reference>
    <citation>Morrison MA, Payabvash S, Chen Y, Avadiappan S, Shah M, Zou X, Hess CP, Lupo JM. A user-guided tool for semi-automated cerebral microbleed detection and volume segmentation: Evaluating vascular injury and data labelling for machine learning. Neuroimage Clin. 2018 Aug 4;20:498-505. doi: 10.1016/j.nicl.2018.08.002. eCollection 2018.</citation>
    <PMID>30140608</PMID>
  </reference>
  <reference>
    <citation>Zafar A, Quadri SA, Farooqui M, Ikram A, Robinson M, Hart BL, Mabray MC, Vigil C, Tang AT, Kahn ML, Yonas H, Lawton MT, Kim H, Morrison L. Familial Cerebral Cavernous Malformations. Stroke. 2019 May;50(5):1294-1301. doi: 10.1161/STROKEAHA.118.022314. Review.</citation>
    <PMID>30909834</PMID>
  </reference>
  <reference>
    <citation>Mabray MC, Caprihan A, Nelson J, McCulloch CE, Zafar A, Kim H, Hart BL, Morrison L. Effect of Simvastatin on Permeability in Cerebral Cavernous Malformation Type 1 Patients: Results from a Pilot Small Randomized Controlled Clinical Trial. Transl Stroke Res. 2020 Jun;11(3):319-321. doi: 10.1007/s12975-019-00737-4. Epub 2019 Oct 23.</citation>
    <PMID>31643041</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Hemangioma, Cavernous, Central Nervous System</mesh_term>
    <mesh_term>Hemangioma, Cavernous</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Available data will be released to the Rare Diseases Clinical Research Network repository and will become available to the scientific community one year after publication of planned analyses, or after a period of 5 years from the date when the data were collected, whichever comes first</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

